AZNAstraZenecaRunning, no new patients
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Hepatocellular Carcinoma · Biliary Tract Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 294 (planned)
- Started
- Apr 24, 2023
- Main results expected
- Oct 27, 2026
- Fully finished
- Oct 28, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response rate (ORR)
Measured over: Through study completion, an average of 2 years
The number of participants with adverse events/serious adverse events
Measured over: Through study completion, an average of 2 years
Progression free survival (PFS)
Measured over: Through study completion, an average of 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05775159 · record last updated 2026-08-24 · checked 2026-11-09 15:47 UTC